Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · §2

Draft standard CEI-MS-07: Sub-visible particulate matter in… — submissions

The 13 submissions received, published in full with declared interests and secretariat responses.

Document identifier
CEI-CP-088/2
Series
Public comment period
Version
1.0
Published
21 Jul 2026
Last reviewed
21 Jul 2026
Next review
21 Jul 2027
Identifier
10.71829/cei.cp.88
Certainty
Not rated
Cycle
2026 Q3
Window
21 Jul 2026 – 19 Sep 2026
Status
Open
Submissions
13

§2Submissions and responses

13 submissions were received. Each is published in full below with its declared interest, the secretariat response and the disposition. The Institute publishes submissions it did not accept in the same form as those it did.

Dr Liesbeth Nordhagen, PharmD, MSc Global regulatory policy, marketing-authorisation holder · submitting on regulatory science · industry submission
DRAFT-PARTICULATE-/001 received 24 Jul 2026

The additional determinations required would materially increase release testing cost

The respondent read the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions and has confined this submission to a single requirement.

The submission is made on behalf of a manufacturer. It states that the draft adds two determinations to those in existing compendial practice, and estimates the additional analytical burden per batch.

The submission does not dispute the analytical reasoning and asks that one of the two be made conditional rather than universal.

Declared interest. Is an employee of a marketing-authorisation holder for a compound named in the draft. This submission is made on behalf of that company and is identified as an industry submission throughout.
Secretariat responseAccepted in part04 Oct 2026

The secretariat accepts this submission in part. One determination is made conditional on a stated risk factor. The other is retained because the evidence supplied by the respondent does not bear on whether it is necessary, only on what it costs.

One of the two determinations is now required only where the stated risk factor is present, with the factor defined in the scope, and the other is retained as a universal requirement with the reasoning stated. The submission is identified as an industry submission.

Professor Bartolomeu Nkosi-Lindegaard, PhD Professor of Regulatory Science · submitting on regulatory science
DRAFT-PARTICULATE-/002 received 29 Jul 2026

The standard does not require retention of the primary data

This submission addresses the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions from the standpoint of a reader who will act on a result produced under it.

The respondent states that a reported figure cannot be checked without the chromatogram or spectrum from which it was derived, and that the draft requires only the figure.

The respondent proposes a retention requirement with a stated period.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseNoted, no amendment05 Oct 2026

The secretariat notes this submission. Retention is addressed in the certificate-of-analysis minimum data standard, which requires that primary data be retained and be identifiable from the certificate, and which applies to every determination reported on a certificate.

No amendment arises. The requirement exists in the standard that governs reporting rather than in each determination standard, and the cross-reference has been added here so that a reader working from this document alone can find it.

Dr Eamon Immelmann, PhD (Chemistry), CChem Independent analytical consultancy · submitting on analytical chemistry
DRAFT-PARTICULATE-/003 received 07 Aug 2026

The scope does not say which materials the standard excludes

This is a submission on the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions, made by a respondent who applies comparable procedures daily.

The scope states what the standard applies to. The respondent states that in practice the difficult question is whether a borderline material is in scope, and that the draft leaves it to be inferred.

The respondent proposes an explicit exclusion list.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted06 Oct 2026

The secretariat accepts this submission. A scope stated only positively is a scope that will be stretched.

The scope now states both what the standard applies to and what it does not, with the excluded classes named and, where another standard covers them, cross-referenced.

Dr Marisol Dunmore-Ekpo, MD, MSc (Clinical Trials) Independent evidence-synthesis consultancy · submitting on evidence synthesis
DRAFT-PARTICULATE-/004 received 10 Aug 2026

Absence of evidence is presented in a form a reader will take as negative evidence

The respondent submits on CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions.

Where the Institute has identified no study, the draft states that no evidence was found. In several places that sentence sits immediately after a paragraph describing an adverse outcome, and the juxtaposition invites the reading that the compound was studied and found wanting.

The respondent proposes a standing formulation, used identically wherever the situation arises, distinguishing an outcome that was studied and not demonstrated from an outcome that has not been studied at all.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted27 Sep 2026

The secretariat accepts this submission. The two states are different, they support different decisions, and the draft rendered them in language a reader could not reliably separate.

A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at a glance.

Dr Jolanta Uttridge, PhD (Pharmaceutics) University department of pharmacy practice · submitting on pharmaceutics
DRAFT-PARTICULATE-/005 received 17 Aug 2026

The standard should state a pass limit

The respondent’s comment on the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions arises from performing examinations of this kind in a pharmacy setting.

The respondent states that a standard which reports a figure without a limit leaves the reader without a criterion, and that suppliers will set their own.

The respondent proposes a universal acceptance limit for the determination.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseNot accepted05 Oct 2026

The secretariat does not accept this submission. An appropriate limit depends on the compound, the presentation and the intended route, none of which the standard fixes.

The standard states performance and reports the figure as determined. Setting a universal limit would attach a pass or fail to materials whose acceptable ranges genuinely differ, which would be a stronger claim than the Institute can support. The submission remains published in full and the point is recorded in the limitations.

Dr Ottoline Fitzgerald-Nwosu, PhD (Chemistry), MRSC Academic peptide-chemistry group · submitting on peptide chemistry
DRAFT-PARTICULATE-/006 received 20 Aug 2026

The standard assumes a reference standard of known assigned content

Having read the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions, the respondent puts one point to the secretariat.

The respondent states that for many compounds in scope no reference standard with an assigned content exists, and that the standard as drafted has nothing to say to a laboratory in that position.

The respondent proposes that the standard state what can be determined without one and how such a determination should be labelled.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted03 Oct 2026

The secretariat accepts this submission. A standard applicable only where a reference standard exists is silent in the cases most in need of it.

The standard now states which determinations remain available without a reference standard of assigned content, requires that such determinations be labelled as relative rather than absolute, and requires the assumption used in place of an assigned content to be stated.

Thaddeus Isaksen-Balogun, MSc (Epidemiology) Academic biostatistics group · submitting on biostatistics
DRAFT-PARTICULATE-/007 received 21 Aug 2026

A single determination is permitted where duplicates would be inexpensive

The respondent notes that CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions will be applied to lyophilised material whose appearance changes on storage, and submits with that in view.

The respondent states that the draft permits a result to be reported from one injection, and that the marginal cost of a duplicate is small relative to the value of detecting a preparation error.

The respondent proposes that duplicate determinations be mandatory.

Declared interest. Is a member of the Institute's external reviewer register but did not review the document under consultation.
Secretariat responseAccepted in part15 Oct 2026

The secretariat accepts this submission in part. Duplicate preparation and injection are required, and a criterion for agreement between them is stated. The proposal to require full duplicate sample preparation on separate days is declined as disproportionate.

The standard now requires duplicate preparation and injection with a stated maximum difference between the two, and requires that a difference exceeding it be investigated before any figure is reported.

Stellan Cholmondeley-Ade, MSc (Clinical Pharmacy) Regional hospital pharmacy department · submitting on medicines information
DRAFT-PARTICULATE-/008 received 26 Aug 2026

The search date is not on the face of the document

The respondent has read CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions in draft and makes one submission.

The draft carries a publication date and a review date but not the date on which the evidence was last searched. Those are three different dates and only the third tells a reader how current the assessment is. A document published in one quarter may rest on a search run two quarters earlier, and nothing on the page allows that gap to be measured.

The respondent proposes that the search date be printed adjacent to every certainty rating rather than in the methods section, on the ground that a reader who acts on a rating is unlikely to have read the methods section first.

The respondent notes submission 004 above and does not repeat the ground it covers.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted05 Oct 2026

The secretariat accepts this submission. The distinction between publication, review and search dates is real and the draft did not make it visible where it mattered.

The search date is now printed adjacent to every certainty rating and is carried in the document metadata, so that the interval between the search and the reading is visible without reference to the methods section.

Dr Liesbeth Achterberg, PhD (Clinical Biochemistry) ISO/IEC 17025-accredited contract testing laboratory · submitting on clinical biochemistry
DRAFT-PARTICULATE-/009 received 30 Aug 2026

The standard should require documented operator competence

The respondent submits on CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions. The point would apply equally to any document in the series.

The respondent states that the determination described requires judgement, particularly at the integration step, and that a competence requirement would improve consistency more than any change to the criteria.

The respondent proposes that conformance be conditional on documented operator training.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseNot accepted28 Sep 2026

The secretariat does not accept this submission. Operator competence is a quality-system matter governed by accreditation requirements the Institute does not administer and cannot verify.

The standard states performance and remains silent on competence. Where judgement affects the result, as at the integration step, the standard requires the judgement to be recorded rather than the operator to be qualified, which is the part the Institute can check from a report. The submission remains published in full.

Dr Theodora Trelawney, PhD (Clinical Biochemistry) ISO/IEC 17025-accredited contract testing laboratory · submitting on clinical biochemistry
DRAFT-PARTICULATE-/010 received 31 Aug 2026

Nothing requires a laboratory to demonstrate ongoing performance

The respondent submits on the draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions. A physical-quality attribute is informative and routinely left unreported, and a standard that makes one routine is worth having.

The respondent states that suitability criteria assessed within a run demonstrate that the run worked and not that the laboratory performs consistently over time.

The respondent proposes participation in a proficiency scheme as a condition of conformance.

The respondent’s submission overlaps with submission 004 and was prepared without sight of it.

Declared interest. No financial or non-financial interest to declare in relation to the subject of this consultation.
Secretariat responseAccepted in part04 Oct 2026

The secretariat accepts this submission in part. A trend requirement on system suitability data is added. Proficiency scheme participation is not made a condition of conformance, for the same reason competence requirements are not.

The standard now requires that system suitability results be trended across runs and that a determination report whether the trend was within the laboratory's stated limits, which places the demonstration inside the document the Institute can read.

Dr Vasilisa Immelmann, PharmD, PhD Health-technology assessment agency · submitting on regulatory science
DRAFT-PARTICULATE-/011 received 05 Sep 2026

A conformance claim is not defined and will be made loosely

This is a submission on CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions.

The respondent states that the draft nowhere defines what it means for a determination to conform, and that in the absence of a definition the phrase will be applied to determinations that meet some of the requirements.

The respondent proposes an explicit definition and a requirement that partial conformance be described as such.

The respondent has read submission 009 above and makes this submission independently of it.

Declared interest. Has received consultancy fees from a supplier named in the Institute's supplier assessment set within the preceding two years.
Secretariat responseAccepted10 Oct 2026

The secretariat accepts this submission. An undefined conformance claim is a marketing phrase.

Conformance is now defined as meeting every requirement classified as critical together with the stated system suitability criteria, partial conformance must be described by naming the requirements not met, and a claim of conformance made without the sampling statement is not conformant.

Dr Jolyon Grünbaum-Sowande, PhD (Bioanalysis) Academic mass-spectrometry core facility · submitting on mass spectrometry
DRAFT-PARTICULATE-/012 received 15 Sep 2026

A single method cannot support the conclusion the standard permits

Having read the draft under consultation, which concerns CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions, the respondent submits as follows.

The respondent states that species invisible to this determination will not appear in the result, and that a conclusion about the material as a whole requires an orthogonal method.

The respondent proposes that an orthogonal determination be mandatory.

Declared interest. Holds a personal shareholding, below the Institute's materiality threshold, in a diversified fund with pharmaceutical sector exposure. No direct holding in any named company.
Secretariat responseAccepted in part30 Sep 2026

The secretariat accepts this submission in part. An orthogonal determination is required where a conclusion about the material as a whole is to be drawn. It is not required where the standard is used to report the quantity it measures.

The standard now distinguishes a determination of the measured quantity, which stands alone, from a conclusion about the material, which requires a named orthogonal determination, and states that the second claim made on the strength of the first alone is not conformant.

Dr Hortensia Hollingworth, PhD (Clinical Biochemistry) ISO/IEC 17025-accredited contract testing laboratory · submitting on clinical biochemistry
DRAFT-PARTICULATE-/013 received 18 Sep 2026

The matrix interferes with the determination and no control is required

The draft of CEI-MS-07, Sub-visible particulate matter in reconstituted peptide solutions was read from the standpoint of a laboratory reconstituting material for analysis.

The respondent states that the matrices in scope can suppress or enhance the response, and that without an inhibition and enhancement control a result cannot be attributed to the analyte.

Data showing recovery outside acceptable limits in an uncontrolled matrix accompanied the submission.

Declared interest. Employed by an analytical laboratory that performs contract testing for suppliers, including at least one supplier named in the Institute's assessment set.
Secretariat responseAccepted28 Sep 2026

The secretariat accepts this submission. A determination on an interfering matrix without a validated control establishes nothing, and the draft permitted one.

An inhibition and enhancement control is now required for every determination under this standard, with stated recovery limits, and a determination reported without it is recorded as not conformant rather than as a low result.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.